DOCS vs TEM Stock Comparison: AI Score, Valuation, Performance and Upside
Doximity is a highly profitable, capital-light digital network monetizing physician engagement, while Tempus AI is a faster-growing, still-maturing precision medicine data and diagnostics company investing heavily to scale its AI platform. The comparison generally weighs Doximity's proven profitability against Tempus's higher-growth, higher-risk AI-driven healthcare data opportunity.
This comparison is best used to weigh a proven, highly profitable physician network platform against an earlier-stage, faster-growing AI-driven precision medicine company still working toward consistent profitability.
TEM holds the edge across 3 of 5 key metrics in this comparison. TEM has delivered stronger 1-year price return (-22.61% vs -53.71%), though DOCS has the better forward P/E setup (19.59x vs -2577.61x for TEM). On fundamentals, TEM is growing revenue faster (21.60%), while DOCS maintains the higher operating margin (21.54%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for TEM (+7.74%) than for DOCS (-2.73%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a highly profitable, capital-light healthcare technology platform
- Value consistent free cash flow generation
- Believe physician engagement and pharma marketing spend will keep growing
- Prefer lower business-model risk within healthcare technology
- Want higher-growth exposure to AI-driven precision medicine and genomics
- Are comfortable with a company still working toward sustained profitability
- Believe proprietary clinical data assets will create a durable competitive moat
- Accept reimbursement and regulatory risk typical of diagnostics businesses
| Metric | DOCS | TEM |
|---|---|---|
| AI scorei | 24.3 | 33.6 |
| AI ranki | #3195 | #2058 |
| Latest closei | $31.50 | $71.13 |
| 1M returni | +22.05% | +3.31% |
| 3M returni | +41.83% | +32.73% |
| 6M returni | +29.90% | +30.71% |
| 1Y returni | -53.71% | -22.61% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | DOCS | TEM |
|---|---|---|
| 1Y ago | $4.68K (-53.2%) started 2025-10-16 | $7.81K (-21.9%) started 2025-10-16 |
| 5Y ago | $4.46K (-55.4%) started 2021-10-18 | $17.67K (+76.7%) started 2024-06-14 |
| 10Y ago | $5.94K (-40.6%) started 2021-06-24 | $17.67K (+76.7%) started 2024-06-14 |
Hypothetical — past performance does not guarantee future results.
| Metric | DOCS | TEM |
|---|---|---|
| Market capi | $5.44B | $11.18B |
| Trailing P/Ei | 34.66 | N/A |
| Forward P/Ei | 19.59 | -2577.61 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 7.26 | 8.29 |
| Analyst targeti | $29.67 | $66.73 |
| Target upsidei | -2.73% | +7.74% |
| Metric | DOCS | TEM |
|---|---|---|
| Revenue growthi | 7.30% | 21.60% |
| Earnings growthi | -51.90% | N/A |
| EPS growthi | -51.90% | N/A |
| FCF margini | +36.56% | -6.53% |
| Operating margini | 21.54% | -20.11% |
| Profit margini | 25.48% | -17.77% |
| ROIC proxyi | 17.21% | -67.44% |
| Return on equityi | 17.21% | -67.44% |
| Dividend yieldi | 0.00% | N/A |
| Payout ratioi | 0.00% | N/A |
| Dividend growth streaki | N/A | N/A |
| Betai | 1.22 | 3.58 |
| Debt/equityi | 1.06 | 324.58 |
| Current ratioi | 6.08 | 3.30 |
| Quick ratioi | 5.80 | 3.01 |
Over the past year, DOCS and TEM have moved weakly in the same direction (correlation of 0.27), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | DOCS | TEM |
|---|---|---|---|
| 1Y | Growthi | -53.22% | -21.85% |
| CAGRi | -53.28% | -21.89% | |
| Volatilityi | 64.04% | 74.07% | |
| Sharpe ratioi | -0.94 | -0.03 | |
| Sortino ratioi | -1.31 | -0.05 | |
| Max drawdowni | 73.71% | 55.06% | |
| Current drawdowni | 54.01% | 23.06% | |
| Avg drawdowni | 53.68% | 34.40% | |
| Ulcer Indexi | 56.98% | 36.93% | |
| Max daily dropi | 23.00% | 13.85% | |
| Max wkly dropi | 30.81% | 20.36% | |
| 5Y | Growthi | -55.36% | +76.72% |
| CAGRi | -14.92% | +27.58% | |
| Volatilityi | 65.70% | 97.04% | |
| Sharpe ratioi | -0.00 | 0.68 | |
| Sortino ratioi | -0.00 | 1.08 | |
| Max drawdowni | 78.34% | 59.76% | |
| Current drawdowni | 62.11% | 31.11% | |
| Avg drawdowni | 50.19% | 33.31% | |
| Ulcer Indexi | 53.52% | 36.85% | |
| Max daily dropi | 23.00% | 19.23% | |
| Max wkly dropi | 32.63% | 37.12% | |
| 10Y | Growthi | -40.57% | +76.72% |
| CAGRi | -9.33% | +27.58% | |
| Volatilityi | 69.08% | 97.04% | |
| Sharpe ratioi | 0.12 | 0.68 | |
| Sortino ratioi | 0.20 | 1.08 | |
| Max drawdowni | 82.35% | 59.76% | |
| Current drawdowni | 69.12% | 31.11% | |
| Avg drawdowni | 58.41% | 33.31% | |
| Ulcer Indexi | 61.38% | 36.85% | |
| Max daily dropi | 23.00% | 19.23% | |
| Max wkly dropi | 32.63% | 37.12% |
| Category | DOCS | TEM |
|---|---|---|
| Company | Doximity | Tempus AI |
| Sector | Healthcare | Healthcare |
| Industry | Health Information Services | Health Information Services |
| Core business | Doximity operates a digital platform and professional network for physicians, monetizing through pharmaceutical marketing, hiring, and workflow tools sold to healthcare organizations. | Tempus AI provides AI-powered precision medicine tools, combining genomic sequencing, clinical data, and machine learning to help oncologists and other clinicians personalize treatment decisions. |
| Investor focus | Investors track Doximity's physician user engagement, pharmaceutical marketing client spending, and its high-margin, capital-light profitability profile. | Investors track Tempus's revenue growth from diagnostic testing and data licensing, its path to profitability, and adoption of its AI-driven clinical decision tools by health systems and pharma partners. |
- Dominant physician network with high engagement among U.S. doctors
- High gross margins and consistent free cash flow generation
- Diversified revenue across marketing, hiring, and workflow products
- Large proprietary clinical and molecular dataset supporting AI model development
- Fast-growing testing volume and expanding pharma data licensing partnerships
- Positioned at the intersection of genomics, AI, and precision oncology
- Revenue concentration in pharmaceutical and healthcare system marketing budgets
- Growth increasingly depends on expanding average revenue per client
- Competitive pressure from other digital health engagement platforms
- Still working toward sustained GAAP profitability
- Reimbursement and regulatory risk typical of diagnostic testing businesses
- Valuation reflects significant expectations for continued high growth
Compare more than two at a time
This page is a fixed writeup on DOCS and TEM. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside DOCS and TEM, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.